Literature DB >> 8764021

Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication.

Q Zhang1, Y Hong, D Dorsky, E Holley-Guthrie, S Zalani, N A Elshiekh, A Kiehl, T Le, S Kenney.   

Abstract

The Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1 are both essential for lytic EBV replication. BZLF1 is a transcriptional activator which binds directly to the lytic origin of replication (oriLyt) and plays a critical role in the disruption of viral latency. The BMRF1 protein is required for viral polymerase processivity. Here we demonstrate that the BMRF1 gene product functions as a transcriptional activator and has direct (as well as indirect) interactions with the BZLF1 gene product. The BMRF1 gene product activates an essential oriLyt promoter, BHLF1, but does not activate two other early EBV promoters (BMRF1 and BHRF1). Direct interaction between the BMRF1 and BZLF1 gene products requires the first 45 amino acids of BMRF1 and the bZip domain of BZLF1. The effect of the BZLF1-BMRF1 interaction on early EBV transcription is complex and is promoter specific. The oriLyt BHLF1 promoter is activated by either the BZLF1 or BMRF1 gene product alone and is further activated by the combination of the BZLF1 and BMRF1 gene products. Enhanced activation of BHLF1 transcription by the BMRF1-BZLF1 combination does not require direct interaction between these proteins. In contrast, BZLF1-induced activation of the BMRF1 promoter is inhibited in the presence of the BMRF1 gene product. A point mutation in the BZLF1 protein (amino acid 200), which prevents in vitro interaction with the BMRF1 protein but which does not reduce BZLF1 transactivator function, allows the BZLF1 protein to activate the BMRF1 promoter equally well in the presence or absence of the BMRF1 gene product. Therefore, direct interaction between the BZLF1 and BMRF1 proteins may inhibit BZLF1-induced transcription of the BMRF1 promoter. BZLF1 mutated at amino acid 200 is as efficient as wild-type BZLF1 in promoting replication of an oriLyt plasmid. However, this mutation reduces the ability of BZLF1 to induce lytic replication of the endogenous viral genome in D98/HE-R-1 cells. Our results indicate that functional and physical interactions between the BMRF1 and BZLF1 proteins may modulate the efficiency of lytic EBV infection. The BMRF1 gene product clearly has a transcriptional, as well as replicative, role during lytic EBV infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764021      PMCID: PMC190468     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  cis-acting elements in the lytic origin of DNA replication of Epstein-Barr virus.

Authors:  A Schepers; D Pich; J Mankertz; W Hammerschmidt
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

2.  Epstein-Barr virus (EBV) replication and expressions of EA-D (BMRF1 gene product), virus-specific deoxyribonuclease, and DNA polymerase in EBV-activated Akata cells.

Authors:  M Daibata; T Sairenji
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

3.  Functional expression and characterization of the Epstein-Barr virus DNA polymerase catalytic subunit.

Authors:  T Tsurumi; A Kobayashi; K Tamai; T Daikoku; R Kurachi; Y Nishiyama
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

4.  Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1.

Authors:  E B Quinlivan; E A Holley-Guthrie; M Norris; D Gutsch; S L Bachenheimer; S C Kenney
Journal:  Nucleic Acids Res       Date:  1993-07-11       Impact factor: 16.971

5.  Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro.

Authors:  T Tsurumi; T Daikoku; R Kurachi; Y Nishiyama
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Acidic transcription factors alleviate nucleosome-mediated repression of DNA replication of bovine papillomavirus type 1.

Authors:  R Li; M R Botchan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

7.  Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1.

Authors:  E Flemington; S H Speck
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

8.  DNA-binding-defective mutants of the Epstein-Barr virus lytic switch activator Zta transactivate with altered specificities.

Authors:  E K Flemington; J P Lytle; C Cayrol; A M Borras; S H Speck
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

9.  Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency.

Authors:  Q Zhang; D Gutsch; S Kenney
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

10.  A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus.

Authors:  A Schepers; D Pich; W Hammerschmidt
Journal:  EMBO J       Date:  1993-10       Impact factor: 11.598

View more
  49 in total

1.  The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex.

Authors:  K Fujii; N Yokoyama; T Kiyono; K Kuzushima; M Homma; Y Nishiyama; M Fujita; T Tsurumi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94.

Authors:  Edward Gershburg; Joseph S Pagano
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.

Authors:  Ayumi Kudoh; Tohru Daikoku; Yutaka Sugaya; Hiroki Isomura; Masatoshi Fujita; Tohru Kiyono; Yukihiro Nishiyama; Tatsuya Tsurumi
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

4.  The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase.

Authors:  Paula M Krosky; Moon-Chang Baek; Wan Jin Jahng; Imma Barrera; Robert J Harvey; Karen K Biron; Donald M Coen; Phiroze B Sethna
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

5.  Evidence for DNA hairpin recognition by Zta at the Epstein-Barr virus origin of lytic replication.

Authors:  Andrew J Rennekamp; Pu Wang; Paul M Lieberman
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

6.  Initiation of Epstein-Barr virus lytic replication requires transcription and the formation of a stable RNA-DNA hybrid molecule at OriLyt.

Authors:  Andrew J Rennekamp; Paul M Lieberman
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

7.  Tetrameric ring formation of Epstein-Barr virus polymerase processivity factor is crucial for viral replication.

Authors:  Sanae Nakayama; Takayuki Murata; Yoshihiro Yasui; Kazutaka Murayama; Hiroki Isomura; Teru Kanda; Tatsuya Tsurumi
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

8.  Amino acids in the basic domain of Epstein-Barr virus ZEBRA protein play distinct roles in DNA binding, activation of early lytic gene expression, and promotion of viral DNA replication.

Authors:  Lee Heston; Ayman El-Guindy; Jill Countryman; Charles Dela Cruz; Henri-Jacques Delecluse; George Miller
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

9.  The Epstein-Barr virus protein BMRF1 activates gastrin transcription.

Authors:  Elizabeth A Holley-Guthrie; William T Seaman; Prasanna Bhende; Juanita L Merchant; Shannon C Kenney
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

10.  The Epstein-Barr virus replication protein BBLF2/3 provides an origin-tethering function through interaction with the zinc finger DNA binding protein ZBRK1 and the KAP-1 corepressor.

Authors:  Gangling Liao; Jian Huang; Elizabeth D Fixman; S Diane Hayward
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.